{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:40:10Z","timestamp":1771386010667,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A study on 315 patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings was performed to determine risk factors for acute GVHD (aGVHD). Recipients of a dose of CD34+ cells (\u00d7\u2009106\/kg) of 2 or less, more than 2 to 4, and more than 4 had a cumulative incidence of aGVHD grades I-IV of 21%, 35%, and 43%, respectively (log-rankP\u2009=\u2009.01); similarly, recipients of a dose of CD3+ cells (\u00d7\u2009106\/kg) of 0.05 or less, more than 0.05 to 0.1, and more than 0.1 had a cumulative incidence of aGVHD grades I-IV of 18%, 35%, and 44%, respectively (log-rankP\u2009=\u2009.007). Using a Cox regression model, 4 independent factors for aGVHD I-IV were identified: increased CD34+cell dose (P\u2009=\u2009.02), increased CD3+ cell dose (P\u2009=\u2009.02), female patients (P\u2009=\u2009.01), and higher patient age (&amp;gt;\u200942 years) (P\u2009=\u2009.007). This study shows, for the first time in T-cell\u2013depleted transplantations, a positive correlation between the number of CD34+ cells and aGVHD and, also, that the number of CD3+ cells necessary to initiate aGVHD is lower than previously reported.<\/jats:p>","DOI":"10.1182\/blood-2001-11-0057","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:33:52Z","timestamp":1034361232000},"page":"724-727","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings"],"prefix":"10.1182","volume":"100","author":[{"given":"Alvaro","family":"Urbano-Ispizua","sequence":"first","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Ciril","family":"Rozman","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Pedro","family":"Pimentel","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Salut","family":"Brunet","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Jaime","family":"Pe\u0301rez-Oteyza","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Christelle","family":"Ferra\u0301","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Javier","family":"Zuazu","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Alzira","family":"Carvalhais","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Jose Luis","family":"D\u0131\u0301ez","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Ildefonso","family":"Espigado","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Adria\u0301n","family":"Alegre","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Fernando","family":"Campilho","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Jesu\u0301s","family":"Odriozola","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Miguel Angel","family":"Sanz","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Jordi","family":"Sierra","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Javier","family":"Garc\u0131\u0301a-Conde","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]},{"given":"Emili","family":"Montserrat","sequence":"additional","affiliation":[{"name":"From the Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espan\u0303ol de Trasplante Hemopoye\u0301tico) and Instituto Portugue\u0302s de Oncologia\u2014Porto. Participating centers are listed in the  at the end of this article."}]}],"member":"234","reference":[{"key":"2020021221083257600_B1","first-page":"147","article-title":"Graft-versus-host disease.","volume-title":"Bone Marrow Transplantation: Biological Mechanisms and Clinical Practice.","author":"Van Bekkum","year":"1985"},{"key":"2020021221083257600_B2","first-page":"47","article-title":"Retrospectives and perspectives in bone marrow transplantation.","volume":"4(suppl 4)","author":"Van Bekkum","year":"1989","journal-title":"Bone Marrow Transplant."},{"key":"2020021221083257600_B3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM198302103080602","article-title":"Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.","volume":"308","author":"Storb","year":"1983","journal-title":"N Engl J Med."},{"key":"2020021221083257600_B4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jama.1981.03310360024017","article-title":"Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia.","volume":"245","author":"Bortin","year":"1981","journal-title":"JAMA."},{"key":"2020021221083257600_B5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1987.tb06160.x","article-title":"Risk factors for acute graft-versus-host disease.","volume":"67","author":"Gale","year":"1987","journal-title":"Br J Haematol."},{"key":"2020021221083257600_B6","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V80.7.1838.1838","article-title":"Acute graft-versus-host disease. Analysis of risk factors after allogeneic marrow transplantation and prohylaxis with cyclosporine and methotrexate.","volume":"80","author":"Nash","year":"1992","journal-title":"Blood."},{"key":"2020021221083257600_B7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bmt.1701386","article-title":"Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immuno-adsorption or immunomagnetic technique. Spanish Group of Allo-PBT.","volume":"22","author":"Urbano-Ispizua","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"2020021221083257600_B8","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1182\/blood.V98.8.2352","article-title":"Allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings: detrimental effect of a high number of donor CD34+ cells?","volume":"98","author":"Urbano-Ispizua","year":"2001","journal-title":"Blood."},{"key":"2020021221083257600_B9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone marrow transplantation.","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med."},{"key":"2020021221083257600_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/sim.4780120803","article-title":"Kaplan-Meier. Marginal or conditional probability curves in summarizing competing risk failure time data?","volume":"12","author":"Pepe","year":"1993","journal-title":"Stat Med."},{"key":"2020021221083257600_B11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample test for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat."},{"key":"2020021221083257600_B12","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood.V88.8.3223.bloodjournal8883223","article-title":"CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematological recovery after allogeneic marrow transplants for hematological malignancies.","volume":"88","author":"Mavroudis","year":"1996","journal-title":"Blood."},{"key":"2020021221083257600_B13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V68.3.770.770","article-title":"T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft versus host disease.","volume":"68","author":"Kernan","year":"1986","journal-title":"Blood."},{"key":"2020021221083257600_B14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2141.2001.02983.x","article-title":"Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back.","volume":"115","author":"Nakamura","year":"2001","journal-title":"Br J Haematol."},{"key":"2020021221083257600_B15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1365-2141.2000.01838.x","article-title":"CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies.","volume":"108","author":"Bahceci","year":"2000","journal-title":"Br J Haematol."},{"key":"2020021221083257600_B16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V97.2.383","article-title":"The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings.","volume":"97","author":"Urbano-Ispizua","year":"2001","journal-title":"Blood."},{"key":"2020021221083257600_B17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI108680","article-title":"Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival.","volume":"59","author":"Storb","year":"1977","journal-title":"J Clin Invest."},{"key":"2020021221083257600_B18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.1986.tb05545.x","article-title":"Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum.","volume":"63","author":"Atkinson","year":"1986","journal-title":"Br J Haematol."},{"key":"2020021221083257600_B19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.V94.4.1465","article-title":"Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.","volume":"94","author":"Przepiorka","year":"1999","journal-title":"Blood."},{"key":"2020021221083257600_B20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bmt.1701259","article-title":"T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells.","volume":"21","author":"Rondelli","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"2020021221083257600_B21","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V91.10.3892","article-title":"Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells.","volume":"91","author":"Ryncarz","year":"1998","journal-title":"Blood."},{"key":"2020021221083257600_B22","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia.","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood."},{"key":"2020021221083257600_B23","first-page":"133","article-title":"Graft-versus-host disease following transplantation of \u2018one log\u2019 versus \u2018two log\u2019 T-lymphocyte-depleted bone marrow from HLA-identical donors.","volume":"1","author":"Lowenberg","year":"1986","journal-title":"Bone Marrow Transplant."},{"key":"2020021221083257600_B24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood.V75.6.1370.bloodjournal7561370","article-title":"Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial.","volume":"75","author":"Wagner","year":"1990","journal-title":"Blood."},{"key":"2020021221083257600_B25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood.V75.6.1356.1356","article-title":"Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.","volume":"75","author":"Schattenberg","year":"1990","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/2\/724\/1683543\/h81402000724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/2\/724\/1683543\/h81402000724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:12:17Z","timestamp":1581559937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/2\/724\/88959\/Risk-factors-for-acute-graftversushost-disease-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,15]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2001-11-0057","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7,15]]}}}